TARGINTA
LIVE

Serial Number

79309367

Owner

Targinta AB

Attorney

Julie A. Greenberg

Filing Date

Feb 4, 2021

Add to watchlist:

No watchlists yet
View on USPTO

TARGINTA Trademark

Serial Number: 79309367 • Registration: 6784066

TARGINTA is a trademark filed by Targinta AB on February 4, 2021. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Targinta AB

Scheelevägen 8

Entity Type: 99

Trademark Details

Filing Date

February 4, 2021

Registration Date

July 12, 2022

Published for Opposition

April 26, 2022

Goods & Services

Scientific research; laboratory testing services, namely, scientific research, diagnosis, testing and analysis in the fields of medicine, chemistry, stem cells, RNA, DNA, antibodies and proteins; basic and clinical research in the field of respiratory science and medicine, in particular in relation to the development of medicines; research and development services in the field of diagnostic preparations; quality control for others

Biological preparations for use in industry and science; stem cells for research or scientific purposes; antibodies for research and industrial purposes, namely, Biochemicals in the nature of monoclonal antibodies for in vitro scientific or research use, Laboratory chemicals in the nature of an antibody reagent used for the detection of antigens in cell and tissue analysis for in vitro diagnostic use, Diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents to monitor toxicity of drugs; DNA and RNA for scientific and industrial purposes, namely, Test particles for biodetection systems, biological analogues and microscopic carrier beads with chemically attached DNA fragments for use in testing the operation of equipment used for analyzing air for the presence of harmful biological substances, Reagent kits comprising generic DNA circle, DNA primers, polymerase and buffers for use in biotechnology fields, Reagent kit comprising enzyme and chemicals for in vitro transcription of RNA and modified RNA, Gene-based RNA molecular network biomarker reagents for research purposes; proteins for use in science being protein in raw material form for scientific research; chemical test kits, consisting of stem cells, antibodies and proteins, for scientific and industrial purposes for laboratory or research use; reagents for scientific purposes; diagnostic reagents for scientific purposes, not for medical or veterinary purposes; analytical preparations being Chemical buffer and standard solutions used in analytical chemistry, Reagents used for analytical moisture determinations, Reagents for use in scientific apparatus for chemical or biological analysis, Laboratory chemicals in the nature of an antibody reagent used for the detection of antigens in cell and tissue analysis for in vitro diagnostic use, Chemical substances for analyses in laboratories, other than for medical or veterinary purposes for scientific purposes related to cancer treatment and therapies

Pharmaceutical and veterinary preparations for the treatment of cancer and for cancer therapies used in the treatment of cancer; stem cells for medical purposes; stem cells for medical and veterinary use; DNA and RNA for medical and veterinary purposes, namely, gene-based RNA molecular network biomarker reagents for medical diagnosis purposes, Medical therapeutic preparations in the nature of biologically active antisense DNA or RNA compounds, Biological products for medical use in recombinant DNA technology in the nature of DNA products allowing recombinant production of polypeptides and monoclonal antibodies; surgical implants grown from stem cells comprising living tissues; antibodies, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; biological preparations for the treatment of cancer for medical and veterinary purposes; diagnostic kit consisting of stem cells, monoclonal antibodies and proteins for use in disease testing for medical and veterinary purposes; Reagents for medical use, namely, reagents for medical diagnosis and analysis; diagnostic preparations for medical and veterinary use

Filing History

TEAS CHANGE OF CORRESPONDENCE RECEIVED
May 6, 2026 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
May 6, 2026 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
May 6, 2026 REAP
FINAL DECISION TRANSACTION PROCESSED BY IB
Nov 7, 2022 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Oct 19, 2022 FICS
FINAL DISPOSITION PROCESSED
Oct 19, 2022 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Oct 12, 2022 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jul 12, 2022 NRCC
REGISTERED-PRINCIPAL REGISTER
Jul 12, 2022 R.PR
NOTIFICATION PROCESSED BY IB
May 3, 2022 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 26, 2022 NPUB
PUBLISHED FOR OPPOSITION
Apr 26, 2022 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Apr 13, 2022 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Apr 13, 2022 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 6, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 24, 2022 CNSA
EXAMINER'S AMENDMENT ENTERED
Mar 24, 2022 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Mar 24, 2022 GNEN
EXAMINERS AMENDMENT E-MAILED
Mar 24, 2022 GNEA
EXAMINERS AMENDMENT -WRITTEN
Mar 24, 2022 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 16, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 15, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 15, 2022 TROA
ASSIGNED TO EXAMINER
Mar 9, 2022 DOCK
REFUSAL PROCESSED BY IB
Oct 25, 2021 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Sep 27, 2021 RFCS
REFUSAL PROCESSED BY MPU
Sep 27, 2021 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Sep 10, 2021 RFCR
NON-FINAL ACTION WRITTEN
Sep 9, 2021 CNRT
ASSIGNED TO EXAMINER
Aug 27, 2021 DOCK
APPLICATION FILING RECEIPT MAILED
Apr 27, 2021 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 23, 2021 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Apr 22, 2021 REPR